TruScreen Group Limited’s (ASX:TRU) Dr Sulaiman Al-Habib Medical Group has installed the first tranche of four TruScreen devices for commercial use, for the screening of cervical cancer in Saudi Arabia.
Dr Sulaiman Al-Habib Medical Group (DSAMG) is the largest private hospital network in the Middle East. The adoption of TruScreen’s screening technology by DSAMG private hospitals will be important reference sites for further market access in neighbouring Middle Eastern nations.
This installation follows from the previously announced successful completion of the clinical evaluation by DSAMG network, followed by a successful tender by BettaLife Trading FZC (BettaLife) (Truescreen’s distributor in the Middle East).
Truscreen recently completed the analysis of results from its cervical screening clinical evaluation of TruScreen Ultra and Liquid Based Cytology (LBC).
A cohort of 507 women were examined with TruScreen and LBC across multiple medical centres of DSAMG. The preliminary results confirmed that TruScreen’s sensitivity was 83.3% (LBC: 66%) and specificity was 95% (LBC 98%).
I am very pleased that the Dr Sulaiman Al-Habib Medical Group have approved and will use TruScreen technology to advance the screening for cervical cancer in their hospital network,” CEO, Dr Beata Edling, said.
“We congratulate BettaLife, our partner in Saudi Arabia, on reaching this important milestone which will support the expansion of the TruScreen operations in the Middle East.”
